Oral Biologics & Biosimilars Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts
Discover trends, market shifts, and competitive outlooks for the oral biologics & biosimilars industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
#What is the Projected CAGR for the Oral Biologics & Biosimilars Market Size from 2025 to 2034?
The market for oral biologics and biosimilars has seen a significant expansion in its size over the recent years. The market is projected to escalate from a worth of $7.04 billion in 2024 to $8.69 billion in 2025, navigating a compound annual growth rate (CAGR) of 23.5%. This substantial growth during the historic period is ascribed to factors such as enhanced collaborations and alliances among the market participants for superior insights, augmented requirement for immunology, rising demand catalysed by cost-effective manufacturing procedures, an aging population, initiatives by the government, and the capacity to set high prices.
Expectations are high for the oral biologics & biosimilars market, with projections of remarkable growth in the coming years. The market’s worth is estimated to reach $19.13 billion by 2029, growing at a compound annual growth rate (CAGR) of 21.8%. Factors contributing to this prospective growth involve vigorous research and development efforts for oral biologics, preference for pills over injections, unhealthy lifestyle adoption, technological advancements, oral biologics’ convenience, improved healthcare accessibility, biologics reimbursement, the upswing in biosimilars, and the growing occurrence of chronic diseases. During the forecast period, considerable trends encompass investing in the oral biologics market to leverage significant profit margins, transitioning to biologics with the field’s increasing innovation rate, and creating drugs based on microneedle injectors for heightened bioavailability and to counteract the side effects present in the subcutaneous route.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp
What External and Internal Drivers Are Contributing to the Growth of theOral Biologics & Biosimilars Market?
The escalating incidence of chronic illnesses like arthritis, asthma, and cancer is anticipated to boost the expansion of the oral biologics and biosimilar market. Lengthy work hours, scarce physical exercise, and detrimental food and beverage habits increase the occurrence of these chronic diseases, leading to wider usage of biologics for their treatment. Biologics bolster the immune system’s response towards cancer cells, assisting inherent bodily defenses in eliminating harmful cells. A United Nations article from a US-based intergovernmental organization forecasts that by 2030, chronic diseases will be responsible for 70% of all global fatalities, and it’s projected to cause almost 60% of all deaths globally. Consequently, the swelling prevalence of chronic diseases is fostering the growth of the biologics and biosimilar market.
What Segment Types Define the Oral Biologics & Biosimilars Market Structure?
The oral biologics & biosimilars market covered in this report is segmented –
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies
2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases
3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators
2) By Interleukin Inhibitors: IL-1 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors
3) By Tumor Necrosis Factor-Alpha Inhibitors: TNF-? Blockers, Monoclonal Antibodies Targeting TNF-?
4) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants
5) By GPCR Modulators: Agonists, Antagonists, Biased Ligands
6) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=6830&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Oral Biologics & Biosimilars Market?
North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Oral Biologics & Biosimilars Market?
The emergence of fresh insulin biosimilars has been identified as a significant trend gaining traction in the oral biologics and biosimilar market. Pioneers in the oral biologics and biosimilar market are channeling their resources into the development of a biosimilar equivalent of insulin in an attempt to secure a larger market share. For instance, Amgen, a biotechnology organisation based in the US, launched Amjevita, a biosimilar to Humira in January 2023. The introduction of this product is parallel to advancements made in the domain of insulin biosimilars. The company’s objective is to reduce expenditure and enhance accessibility to essential treatments. Amjevita offers a cost-effective solution for conditions such as arthritis and Crohn’s disease and makes treatments for diabetes employing insulin biosimilars more affordable and approachable. These advancements are escalating competition and encouraging progress in biologics. The firm prioritises the discovery, production and delivery of cutting-edge human therapeutics.
View the full report here:
What Is the Definition of the Oral Biologics & Biosimilars Market?
Biologics are drugs made from living cells using highly complex technology, while biosimilars are created to function similarly to biologics but are not identical to biologics. The oral biologics and biosimilars comprise biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer’s, multiple sclerosis, HIV or AIDS, and other serious conditions and are used to treat chronic diseases such as diabetes, arthritis, and cancer.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6830
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
